Psoriasis stem cell therapy — your questions answered (2026)
About stem cell therapy for Psoriasis
Psoriasis is a chronic immune-mediated inflammatory disease characterised by dysregulated T-cell signalling and keratinocyte proliferation. Genetic susceptibility and environmental triggers both contribute. Mesenchymal stromal cells (MSCs) and extracellular vesicles are being studied for proposed immunomodulatory effects involving pathways such as IL-17 and regulatory T-cell signalling. Those mechanisms have not established comparative clinical benefit against approved psoriasis treatments. The registry table on this page lists relevant studies and their current recruitment status.
The evidence for Psoriasis
Human psoriasis studies of MSCs and related products are small and heterogeneous. Changes in PASI components, symptoms or biomarkers have not established comparative efficacy against modern approved systemic treatments. Cross-study comparisons with anti-TNF, anti-IL-17 or anti-IL-23 medicines are not reliable without appropriate randomised controls. No pooled response rate is published here because product, dose, route, comparator and follow-up differ too widely for a single figure to be meaningful. The registered studies and their own prespecified endpoints are listed in the registry table on this page.
Private investigational psoriasis cell procedures can involve separate charges for repeat administration, dermatology assessment, laboratory testing, imaging, travel and ongoing standard treatment. Prices do not indicate regulatory approval or comparative effectiveness. Patients should request an itemised written quote and verify sponsor, insurer and patient responsibilities. Effective approved topical, phototherapy, conventional systemic and biologic options must not be delayed for an experimental procedure.
Can stem cells clear psoriasis?
Cell therapy for Psoriasis may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.
Skin vs psoriatic arthritis?
Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.
Will I stop my medication?
Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.
EU cost?
The partner-published indicative range for an Psoriasis programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.
Sources & further reading
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
- Open clinical trials for Psoriasis (ClinicalTrials.gov) ↗
- Peer-reviewed research on PubMed ↗
- ISSCR patient guide — what to ask ↗
- FDA consumer warning on stem-cell therapies ↗
- EMA — advanced-therapy (ATMP) framework ↗